Related Experiment Videos
[Bone marrow aplasia associated to the use of ticlopidine]
Carolina Ruiz1, Tatiana Monroy, Nelson Montaña
1Facultad de Ciencias Médicas, Universidad de Santiago de Chile.
Abstract:
We report a 58 years old male that developed a bone marrow aplasia associated to the use of ticlopidine, prescribed after coronary artery stenting. The patient developed a pneumonia as a complication. He was admitted to the Intermediate Treatment Unit, receiving wide spectrum antimicrobial therapy and a granulocyte colony stimulating factor (Neupogen(r)) with favourable response. Ticlodipine is an effective antiplatelet agent, but has serious hematological and other side effects. Its prescription requires a close follow up and search for complications.
Insights
Ticlopidine, an antiplatelet drug, can cause bone marrow aplasia and pneumonia. Close patient monitoring is crucial due to its serious side effects.
Area of Science:
- Hematology
- Pharmacology
- Internal Medicine
Background:
- Coronary artery stenting is a common procedure to treat coronary artery disease.
- Antiplatelet agents like ticlopidine are frequently prescribed post-stenting to prevent thrombotic events.
- Ticlopidine is known for its efficacy but also carries a risk of significant adverse effects.
Observation:
- A 58-year-old male developed bone marrow aplasia after initiating ticlopidine therapy post-coronary artery stenting.
- The patient subsequently presented with pneumonia, a potential complication of immunosuppression or the underlying condition.
- Treatment involved broad-spectrum antibiotics and granulocyte colony-stimulating factor (Neupogen®).
Findings:
- The case highlights a severe hematological adverse event, bone marrow aplasia, linked to ticlopidine use.
- Pneumonia developed as a complication, necessitating aggressive supportive care.
- The patient showed a favorable response to antimicrobial therapy and Neupogen®, suggesting recovery from the aplastic phase.
Implications:
- Ticlopidine, while effective, necessitates rigorous patient monitoring for hematological toxicity and other serious side effects.
- Early recognition and management of complications like bone marrow aplasia and pneumonia are critical for patient outcomes.
- This case underscores the importance of risk-benefit assessment in prescribing ticlopidine, especially in vulnerable patient populations.